Literature DB >> 29182711

Evaluation of the Neuroprotective Potential of N-Acetylcysteine for Prevention and Treatment of Cognitive Aging and Dementia.

Y Hara1, N McKeehan, P A Dacks, H M Fillit.   

Abstract

Alzheimer's disease is a progressive neurodegenerative disease for which there is no cure and only a few treatments providing little relief. Increased oxidative stress that is associated with aging is strongly implicated in the pathogenesis and progression of Alzheimer's disease. Studies have shown that levels of the endogenous antioxidant glutathione decline at an early stage of Alzheimer's disease with decreased levels correlating with worse cognitive functions. N-acetylcysteine, a drug also widely available as a dietary supplement, is a precursor of L-cysteine, which in turn is a component of glutathione. Because cysteine availability is a limiting factor for glutathione synthesis, treatment with N-acetylcysteine may increase glutathione levels and thereby counter oxidative stress, promote redox -regulated cell signaling, and improve immune responses. In this review, we evaluate the existing literature and the potential of N-acetylcysteine in promoting cognitive health and alleviating cognitive decline associated with dementia. Discussion will also include possible mechanisms of action of N-acetylcysteine, its effects on aging biology, and safety of long-term use. Based on the available literature, a nutraceutical formulation containing N-acetylcysteine among other compounds has shown some pro-cognitive benefits in Alzheimer's patients and older adults, but the evidence for N-acetylcysteine alone is less robust. Although N-acetylcysteine crosses the blood-brain-barrier, low bioavailability is an obstacle. One promising avenue of research may be to explore derivatives of N-acetylcysteine such as N-acetylcysteine amide, which has been reported in preclinical studies to have higher permeability through cellular and mitochondrial membranes with increased central nervous system bioavailability compared to N-acetylcysteine.

Entities:  

Keywords:  Age-related cognitive decline; NAC; NACA; dementia

Mesh:

Substances:

Year:  2017        PMID: 29182711     DOI: 10.14283/jpad.2017.22

Source DB:  PubMed          Journal:  J Prev Alzheimers Dis        ISSN: 2274-5807


  12 in total

Review 1.  Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?

Authors:  Marc J Kaufman; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Neurosci Biobehav Rev       Date:  2019-02-25       Impact factor: 8.989

2.  Kinetics of Glutathione Depletion and Antioxidant Gene Expression as Indicators of Chemical Modes of Action Assessed in Vitro in Mouse Hepatocytes with Enhanced Glutathione Synthesis.

Authors:  Fjodor Melnikov; Dianne Botta; Collin C White; Stefanie C Schmuck; Matthew Winfough; Christopher M Schaupp; Evan P Gallagher; Bryan W Brooks; Edward Spencer Williams; Philip Coish; Paul T Anastas; Adelina Voutchkova-Kostal; Jakub Kostal; Terrance J Kavanagh
Journal:  Chem Res Toxicol       Date:  2019-01-07       Impact factor: 3.739

3.  Screening of the chemoprotective effect of 13 compounds and their mixtures with sodium 2-mercaptoethanesulfonate against 2-chloroethyl ethyl sulfide.

Authors:  Petr Jost; Jaroslav Pejchal; Tomas Kucera; Lubica Muckova; Rudolf Stetina
Journal:  J Appl Biomed       Date:  2019-06-17       Impact factor: 1.797

4.  Evaluation of the Effectiveness of N-Acetylcysteine in the Prevention of Colistin-Induced Nephrotoxicity: A Randomized Controlled Clinical Trial.

Authors:  Sedigheh Mosayebi; Rasool Soltani; Fatemeh Shafiee; Samane Assarzadeh; Atousa Hakamifard
Journal:  J Res Pharm Pract       Date:  2022-05-25

Review 5.  Boosting GSH Using the Co-Drug Approach: I-152, a Conjugate of N-acetyl-cysteine and β-mercaptoethylamine.

Authors:  Rita Crinelli; Carolina Zara; Michaël Smietana; Michele Retini; Mauro Magnani; Alessandra Fraternale
Journal:  Nutrients       Date:  2019-06-07       Impact factor: 5.717

6.  NAC blocks Cystatin C amyloid complex aggregation in a cell system and in skin of HCCAA patients.

Authors:  Michael E March; Alvaro Gutierrez-Uzquiza; Asbjorg Osk Snorradottir; Leticia S Matsuoka; Noelia Fonseca Balvis; Thorgeir Gestsson; Kenny Nguyen; Patrick M A Sleiman; Charlly Kao; Helgi J Isaksson; Birkir Thor Bragason; Elias Olafsson; Astridur Palsdottir; Hakon Hakonarson
Journal:  Nat Commun       Date:  2021-03-23       Impact factor: 14.919

7.  Advanced Age and Neurotrauma Diminish Glutathione and Impair Antioxidant Defense after Spinal Cord Injury.

Authors:  Andrew N Stewart; Ethan P Glaser; Caitlin A Mott; William M Bailey; Patrick G Sullivan; Samir P Patel; John C Gensel
Journal:  J Neurotrauma       Date:  2022-07-13       Impact factor: 4.869

Review 8.  Mitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the Potential.

Authors:  Yashi Mi; Guoyuan Qi; Roberta Diaz Brinton; Fei Yin
Journal:  Antioxid Redox Signal       Date:  2020-04-21       Impact factor: 8.401

9.  Alzheimer's Disease and Its Potential Alternative Therapeutics.

Authors:  Brent Kisby; Juliet T Jarrell; M Enes Agar; David S Cohen; Eric R Rosin; Catherine M Cahill; Jack T Rogers; Xudong Huang
Journal:  J Alzheimers Dis Parkinsonism       Date:  2019-09-13

Review 10.  N-Acetylcysteine: A Review of Clinical Usefulness (an Old Drug with New Tricks).

Authors:  Gerry K Schwalfenberg
Journal:  J Nutr Metab       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.